Pfizer

Pfizer

Pfizer Inc., (faɪzər/ FY-zər) headquartered in Manhattan, New York City, is an American multinational pharmaceutical and biotechnology firm. In 1849, two German immigrants, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891) founded the corporation in New York.

Pfizer is a pharmaceutical company that specializes in immunology, cancer, cardiology, endocrinology, and neurology. The company has numerous blockbuster pharmaceuticals or treatments that produce yearly revenues of more than $1 billion.

Company Profile

Market Cap: 294.40B​​​Industry: Drugs & Biotechnology

Sector(s): Healthcare​​​CEO: Albert Bourla​

Founded: 1849​​​Headquarters: New York

Employees: 79,000

As of May 21, 2022

Pfizer uses research and our worldwide resources to provide treatments and therapies to patients all around the world. Every day, they strive to improve wellness, prevention, treatments, and cures for the world's most feared diseases. They have been working to make a difference for those who rely on them for more than 150 years. Moreover, they cooperate with health care providers, governments, and local communities to promote and extend access to reliable, affordable health care around the world, as part of their role as one of the world's leading creative biopharmaceutical businesses.

Pfizer, a global leader in the biopharmaceutical sector, is always looking for new talent to join an outstanding team and share an ambition for developing innovative medications that improve people's lives.

Early History

Charles Pfizer and Charles F. Erhart, two cousins who had come to the United States from Ludwigsburg, Germany the year before, created Pfizer in 1849. The company, which was based on Bartlett Street in Williamsburgh, New York, developed chemical compounds, including an antiparasitic called santonin. Although it was the production of citric acid that propelled Pfizer's rise in the 1880s, this was an early success. Pfizer proceeded to buy property in the area (now the Williamsburg section of Brooklyn, New York, and, beginning in 1898, the City of Greater New York) to expand its lab and factory, with offices on Flushing Avenue remaining until the 1960s; the Brooklyn plant eventually closed in 2009.

Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) constructed their principal houses in the nearby Clinton Hill neighborhood, famed for its concentration of Gilded Age wealth, following the success of citric acid. Pfizer spent his summers in the opulent Newport, Rhode Island, where he died in 1906.

Due to a shortage of calcium citrate, which Pfizer purchased from Italy for the production of citric acid during World War I, the business began looking for an alternate source. In 1919, Pfizer chemists discovered a fungus that ferments sugar to citric acid and was able to commercialize citric acid manufacturing from this source. As a result, the company gained experience in fermentation technology. During World War II, these talents were put to use in the mass manufacture of penicillin, an antibiotic, in order to heal injured Allied soldiers. The corporation was founded in Delaware on June 2, 1942.

 

From 1950 to 1980

Pfizer had locations in Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico, and the United Kingdom by the 1950s. The business relocated its medical research laboratory activities from New York City to Groton, Connecticut, in 1960. Feldene(piroxicam), a prescription anti-inflammatory medicine introduced by Pfizer in 1980, became the company's first $1 billion product. 

John Powers, Jr. succeeded John McKeen as the company's chief executive officer in 1965. In the 1970s and 1980s, as the neighborhood around its Brooklyn plant began to deteriorate, the company formed a public-private partnership with New York City that included the construction of low- and middle-income housing, the refurbishment of apartment buildings for the homeless, and the establishment of a charter school. Edmund T. Pratt Jr. succeeded John Powers, Jr. as the company's chief executive officer in 1972.

Company of the Year 2007

Forbes selected Nvidia Company of the Year in 2007, recognizing the company's achievements throughout that time period as well as the prior five years. Nvidia announced the completion of its acquisition of PortalPlayer, Inc. on January 5, 2007. Nvidia purchased Ageia, the creator of the PhysX physics engine and physics processing unit, in February 2008. Nvidiarevealed that the PhysX technology would be included in future GPU devices.

Mobile Chipsets and GPUs

After reporting that certain mobile chipsets and GPUs made by the company had "abnormal failure rates" owing to manufacturing issues, Nvidia announced a $200 million write-down on its first-quarter revenue in July 2008. Nvidia, on the other hand, did not specify which products were affected. In September 2008, Nvidia was named in a class action complaint alleging that the defective GPUs were used in Apple Inc., Dell, and HP laptop models. Nvidia struck an agreement in September 2010 to reimburse owners of impacted laptops for repairs or, in some situations, replacement. Nvidia and Intel inked a six-year, $1.5 billion cross-licensing agreement on January 10, 2011, putting an end to any litigation between the two firms.

Finances Data

Now let’s talk about the year 2020. Nvidia reported earnings of US$2.796 billion in the fiscal year 2020, with yearly revenue of US$10.918 billion, down 6.8% from the previous fiscal cycle. In January 2021, Nvidia's stock was trading at over $531 a share, with a market capitalization of over US$328.7 billion.

Nvidia reported sales of $3.87 billion in the second quarter of 2020, up 50% from the same period in 2019. The increased demand for computer technology and the increase in sales. The effects of the pandemic will "likely mirror this transition in enterprise workforce patterns with a higher attention on technologies, such as Nvidia laptops and virtual workstations, that enable distant work and virtual collaboration," according to Colette Kress, the company's financial head.

Year	Revenue in mil. US$	Net income in mil. US$	Total assets in mil. US$	Price per share in US$	Employees
2010	3,326	−68	3,586	12.56	5,706
2011	3,543	253	4,495	15.63	6,029
2012	3,998	581	5,553	12.52	5,042
2013	4,280	563	6,412	13.38	7,974
2014	4,130	440	7,251	17.83	6,384
2015	4,682	631	7,201	23.71	6,384
2016	5,010	614	7,370	53.76	9,227
2017	6,910	1,666	9,841	149.79	10,299
2018	9,714	3,047	11,241	232.38	11,528
2019	11,716	4,141	13,292	174.59	13,277
2020	10,918	2,796	17,315	395.63	13,775
2021	16,675	4,332	28,791	294	18,975
2022	26,914	9,752	44,187	170	22,473